JPMorgan Chase & Co. Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $36.00
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $38.00 to $36.00 in a research note issued to investors on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. DAWN has been the subject of a number of other […]
More Stories
Knowles (NYSE:KN) Updates Q3 2024 Earnings Guidance
Knowles (NYSE:KN – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Thursday morning. The...
Fidelity Disruptive Finance ETF (FDFF) To Go Ex-Dividend on September 20th
Fidelity Disruptive Finance ETF (NASDAQ:FDFF – Get Free Report) declared a quarterly dividend on Thursday, September 19th, NASDAQ reports. Shareholders...
Rezolute (NASDAQ:RZLT) Releases Quarterly Earnings Results, Misses Expectations By $0.14 EPS
Rezolute (NASDAQ:RZLT – Get Free Report) posted its earnings results on Thursday. The company reported ($0.44) earnings per share (EPS)...
MillerKnoll (NASDAQ:MLKN) Issues FY25 Earnings Guidance
MillerKnoll (NASDAQ:MLKN – Get Free Report) issued an update on its FY25 earnings guidance on Thursday morning. The company provided...
Lennar (NYSE:LEN) Updates Q4 2024 Earnings Guidance
Lennar (NYSE:LEN – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Friday morning. The...
Insider Selling: Rent the Runway, Inc. (NASDAQ:RENT) Insider Sells $13,940.00 in Stock
Rent the Runway, Inc. (NASDAQ:RENT – Get Free Report) insider Sarah K. Tam sold 1,394 shares of the stock in...